Christopher Cabell

Christopher Cabell

Director/Board Member chez PULMATRIX, INC.

Fortune : 277 663 $ au 31/03/2024

54 ans
Health Technology
Consumer Services
Commercial Services

Postes actifs de Christopher Cabell

SociétésPosteDébutFin
PULMATRIX, INC. Director/Board Member 23/06/2020 -
Independent Dir/Board Member 23/06/2020 -
Director/Board Member 18/02/2020 -
Corporate Officer/Principal 30/04/2009 -

Historique de carrière de Christopher Cabell

Anciens postes connus de Christopher Cabell

SociétésPosteDébutFin
ZURA BIO LIMITED Chief Tech/Sci/R&D Officer 01/02/2023 15/01/2024
EMERGENT BIOSOLUTIONS INC. Chief Tech/Sci/R&D Officer 01/02/2021 01/01/2023
ARENA PHARMACEUTICALS Chief Tech/Sci/R&D Officer 01/08/2019 01/12/2020
Corporate Officer/Principal 01/10/2017 01/08/2019
Chief Tech/Sci/R&D Officer 01/10/2007 01/09/2017
Duke University School of Medicine Corporate Officer/Principal - -
Chairman - -
░░░░░░░ ░░░░░░ ░░░░░░░░ ░░░░░░░░░░ ░░░░░░░░ - -
░░░ ░░░░░░░ ░░░░ ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ - -
░░░░░░░ ░░░ ░░░░░░░░░░░░░░ ░░░░░░ - -
░░░░ ░░░░░░░░ ░░░░░░░░ ░░░░░░░░░ ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ - -
░░░░░░░░░ ░░░░░░░░░░░░░ ░░░░░ ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ ░░░░░░░░░░ ░░░░░░░░░░
░░░░░░░░░ ░░░░░░░░░░░░░░░░░ ░░░░░░░░░░ -

Formation de Christopher Cabell

Duke University Graduate Degree
The Pennsylvania State University Undergraduate Degree
Duke University School of Medicine Doctorate Degree

Statistiques

Internationale

Etats-Unis 17

Opérationnelle

Chief Tech/Sci/R&D Officer 6
Corporate Officer/Principal 5
Director/Board Member 3

Sectorielle

Health Technology 6
Consumer Services 4
Commercial Services 3

Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Sociétés liées

Sociétés cotées3
EMERGENT BIOSOLUTIONS INC.

Health Technology

PULMATRIX, INC.

Health Technology

ZURA BIO LIMITED

Health Technology

Entreprise privées10

Commercial Services

Technology Services

Health Technology

Health Technology

Government

Health Services

Commercial Services

Technology Services

Distribution Services

Cardiac Safety Research Consortium

Voir les connexions sociétés